Cholangiocarcinoma

Critical Reviews in Oncology/Hematology

Volumn 69, Issue 3, 2009, Pages 259-270

  Mosconi, Stefania ^a   Beretta, Giordano D ^b   Labianca, Roberto ^a   Zampino, Maria G ^c   Gatta, Gemma ^d   Heinemann, Volker ^e  

^a OSPEDALI RIUNITI   (Italy)

^b S Orsola Hospital   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Cholangiocarcinoma; Liver transplantation; Radiation; Surgical resection

Indexed keywords

ALPHA2B INTERFERON; BISMUTH; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PLATINUM; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CACHEXIA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISTANT METASTASIS; FOLLOW UP; HUMAN; LABORATORY TEST; LIVER FAILURE; LIVER TRANSPLANTATION; PALLIATIVE THERAPY; PHOTODYNAMIC THERAPY; PROGNOSIS; REVIEW; SEPSIS; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT PLANNING;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; LIVER TRANSPLANTATION; NEOPLASM STAGING; RISK FACTORS;

EID: 63749123217     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.09.008     Document Type: Review

References (79)

1. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., and Thomas D.B. Cancer incidence in five continents vol. VIII (2002), IARC Press, Lyon [IARC Scientific Publications No. 155]
2. Curado M.P., Edwards B., Shin H.R., et al. Cancer incidence in five continents vol. IX (2007), IARC Scientific Publications, Lyon [No. 160]
3. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
4. Taylor-Robinson S.D., Toledano M.B., Arora S., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48 (2001) 816-820
5. Khan S.A., Taylor-Robinson S.D., Toledano M.B., et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (2002) 806-813
6. Shaib Y.H., Davila J.A., McGlynn K., and El Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 40 (2004) 472-477
7. Khan S.A., Thomas H.C., Davidson B.R., and Taylor-Robinson S.D. Cholangiocarcinoma. Lancet 366 (2005) 1303-1314
8. Lazaridis K.N., and Gores G.J. Cholangiocarcinoma. Gastroenterology 128 (2005) 1655-1667
9. Fava G., Marzioni M., Benedetti A., et al. Molecular pathology of biliary tract cancers. Cancer Lett 250 (2007) 155-167
10. Gores G.J. Cholangiocarcinoma: current concepts and insights. Hepatology 37 (2003) 961-969
11. Broome U., Olsson R., Loof L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38 (1996) 610-615
12. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99 (2004) 523-526
13. Lipsett P.A., Pitt H.A., Colombani P.M., Boitnott J.K., and Cameron J.L. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 220 (1994) 644-652
14. Kubo S., Kinoshita H., Hirohashi K., and Hamba H. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 19 (1995) 637-641
15. Haswell-Elkins M.R., Sithithaworn P., Mairiang E., et al. Immune responsiveness and parasite-specific antibody levels in human hepatobiliary disease associated with Opisthorchis viverrini infection. Clin Exp Immunol 84 (1991) 213-218
16. Okuda K., Nakanuma Y., and Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17 (2002) 1049-1055
17. Bergquist A., Glaumann H., Persson B., and Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 27 (1998) 311-316
18. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 19 (2007) 615-617
19. Sirica A.E. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41 (2005) 5-15
20. Isa T., Tomita S., Nakachi A., et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49 (2002) 604-608
21. Swierczynski S.L., Maitra A., Abraham S.C., et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35 (2004) 357-366
22. Patel T., and Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 23 (2007) 317-323
23. Nakeeb A., Pitt H.A., Sohn T.A., et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224 (1996) 463-473
24. Tsuzuki T., Ogata Y., Iida S., et al. Carcinoma of the bifurcation of the hepatic ducts. Arch Surg 118 (1983) 1147-1151
25. Weinbren K., and Mutum S.S. Pathological aspects of cholangiocarcinoma. J Pathol 139 (1983) 217-238
26. Martin R.C., Klimstra D.S., Schwartz L., et al. Hepatic intraductal oncocytic papillary carcinoma. Cancer 95 (2002) 2180-2187
27. Yeh C.N., Jan Y.Y., and Chen M.F. Influence of age on surgical treatment of peripheral cholangiocarcinoma. Am J Surg 187 (2004) 559-563
28. UICC (International Union Against Cancer). In: Sobin L.H., and Wittekind Ch (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto p. 131-138
29. Siqueira E., Schoen R.E., Silverman W., et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 56 (2002) 40-47
30. Qin X.L., Wang Z.R., Shi J.S., et al. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 10 (2004) 427-432
31. Sharma M.P., and Ahuja V. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective. Trop Gastroenterol 20 (1999) 167-169
32. Hann L.E., Greatrex K.V., Bach A.M., Fong Y., and Blumgart L.H. Cholangiocarcinoma at the hepatic hilus: sonographic findings. AJR Am J Roentgenol 168 (1997) 985-989
33. Zhang Y., Uchida M., Abe T., et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 23 (1999) 670-677
34. Yeh T.S., Jan Y.Y., Tseng J.H., et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 95 (2000) 432-440
35. Slattery J.M., and Sahani D.V. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma?. Oncologist 11 (2006) 913-922
36. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8 (2004) 90-97
37. Saldinger P.F., and Blumgart L.H. Resection of hilar cholangiocarcinoma-a European and United States experience. J Hepatobiliary Pancreat Surg 7 (2000) 111-114
38. Jarnagin W.R., and Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 24 (2004) 189-199
39. Klempnauer J., Ridder G.J., von Wasielewski R., et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 15 (1997) 947-954
40. Su C.H., Tsay S.H., Wu C.C., et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 223 (1996) 384-394
41. Burke E.C., Jarnagin W.R., Hochwald S.N., et al. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228 (1998) 385-394
42. Nimura Y., Hayakawa N., Kamiya J., Kondo S., and Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 14 (1990) 535-543
43. Nakeeb A., Tran K.Q., Black M.J., et al. Improved survival in resected biliary malignancies. Surgery 132 (2002) 555-563
44. Todoroki T., Ohara K., Kawamoto T., et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 581-587
45. Kim S., Kim S.W., Bang Y.J., Heo D.S., and Ha S.W. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 54 (2002) 414-419
46. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221 (1995) 788-797
47. Takada T., Amano H., Yasuda H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (2002) 1685-1695
48. McMasters K.M., Tuttle T.M., Leach S.D., et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174 (1997) 605-608
49. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242 (2005) 451-458
50. Berr F. Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 24 (2004) 177-187
51. Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 125 (2003) 1355-1363
52. Chari R.S., Anderson C.A., and Savarese D.M. Treatment of cholangiocarcinoma II. UpDate (2003)
53. Alden M.E., and Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 28 (1994) 945-951
54. Flickinger J.C., Epstein A.H., Iwatsuki S., Carr B.I., and Starzl T.E. Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 68 (1991) 289-294
55. Crane C.H., Macdonald K.O., Vauthey J.N., et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 53 (2002) 969-974
56. Chen J.S., Jan Y.Y., Lin Y.C., et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 9 (1998) 393-397
57. Patt Y.Z., Jones Jr. D.V., Hoque A., et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14 (1996) 2311-2315
58. Ellis P.A., Norman A., Hill A., et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31A (1995) 1594-1598
59. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101 (2004) 578-586
60. Kim T.W., Chang H.M., Kang H.J., et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14 (2003) 1115-1120
61. Park S.H., Park Y.H., Lee J.N., et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106 (2006) 361-365
62. Kubicka S., Rudolph K.L., Tietze M.K., Lorenz M., and Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48 (2001) 783-789
63. Gebbia V., Giuliani F., Maiello E., et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19 (2001) 4089-4091
64. Alberts S.R., Al-Khatib H., Mahoney M.R., et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103 (2005) 111-118
65. Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 (2005) 2332-2338
66. Mazhar D., Stebbing J., and Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment?. Future Oncol 2 (2006) 509-514
67. André T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR Study. Ann Oncol 15 (2004) 1339-1343
68. Hemming A.W., Reed A.I., Fujita S., Foley D.P., and Howard R.J. Surgical management of hilar cholangiocarcinoma. Ann Surg 241 (2005) 693-699
69. Nagorney D.M., Donohue J.H., Farnell M.B., Schleck C.D., and Ilstrup D.M. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 128 (1993) 871-877
70. Fong Y., Blumgart L.H., Lin E., Fortner J.G., and Brennan M.F. Outcome of treatment for distal bile duct cancer. Br J Surg 83 (1996) 1712-1715
71. Casavilla F.A., Marsh J.W., Iwatsuki S., et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 185 (1997) 429-436
72. Jan Y.Y., Jeng L.B., Hwang T.L., et al. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 43 (1996) 614-619
73. Jan Y.Y., Yeh C.N., Yeh T.S., and Chen T.C. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 11 (2005) 1779-1784
74. Meyer C.G., Penn I., and James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69 (2000) 1633-1637
75. Shimoda M., Farmer D.G., Colquhoun S.D., et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transplant 7 (2001) 1023-1033
76. Sudan D., DeRoover A., Chinnakotla S., et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2 (2002) 774-779
77. Jonas S., and Neuhaus P. The perspective of liver transplantation for cholangiocarcinoma. Liver Transplant 13 (2007) 1358-1361
78. Hochwald S.N., Burke E.C., Jarnagin W.R., Fong Y., and Blumgart L.H. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 134 (1999) 261-266
79. Inal M., Akgul E., Aksungur E., Demiryurek H., and Yagmur O. Percutaneous self-expandable uncovered metallic stents in malignant biliary obstruction. Complications, follow-up and reintervention in 154 patients. Acta Radiol 44 (2003) 139-146